Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Claims 1-26 (Cancelled)

27. (Previously Presented) An isolated polypeptide comprising a peptide sequence having an identity of at least 95% with:
    a) the amino acid sequence of SEQ ID NO. 2; or
    b) the amino acid sequence of amino acids 24 through 189 of SEQ ID NO. 2,
    wherein said polypeptide comprises the G45R SNP and exhibits anti-viral and anti-tumoral activity.

28. (Previously Presented) The isolated polypeptide of claim 27, wherein the peptide sequence has an identity of at least 99% with the amino acid sequence of a) or b), and wherein said polypeptide comprises the G45R SNP and exhibits anti-viral and anti-tumoral activity.

Claims 29-36 (Cancelled)

37. (Currently Amended) A method for ~~preventing or~~ treating ~~a viral disease~~ chronic hepatitis B, chronic hepatitis C, infectious pneumonias, venereal diseases, or genital warts, comprising administering to an individual a therapeutically effective amount of a therapeutic agent comprising the isolated polypeptide of any one of claims ~~27 or 29~~ 27, 28, or 47, with a pharmaceutically acceptable excipient.

Claims 38-39 (Cancelled)

40. (Withdrawn— Currently Amended) A method for identifying a compound with an activity substantially the same as an activity of ~~an interferon alpha-17 protein that comprises a G45R SNP or the same SNP at the equivalent position~~ the polypeptide of claim 27, comprising:

a) determining whether or the extent to which the compound exhibits an activity selected from the group consisting of dendritic cell maturation, cytokine release by CD4+ or CD8+ T-lymphocytes, cytokine release by monocytes, in vitro or in vivo antiviral activity, cellular antiproliferative activity on Daudi Burkitt's cell lines, cellular antiproliferative activity on TF-1 cell lines, *in vitro* or *in vivo* antiviral activity, and any combination of the foregoing activities; and

b) comparing the activity determined in step a) with the activity of said ~~interferon alpha-17 protein~~ polypeptide.

Claim 41 (Cancelled)

42. (Previously Presented) A pharmaceutical composition comprising an isolated polypeptide comprising: a peptide sequence that has an identity of at least 99% with SEQ ID NO. 2, or a portion of said peptide sequence wherein said polypeptide and said portion comprise the G45R SNP and exhibit anti-viral and anti-tumoral activity.

Claims 43-46 (Cancelled)

47. (Previously Presented) An isolated polypeptide comprising:

a) the amino acid sequence of SEQ ID NO. 2; or

b) the amino acid sequence of amino acids 24 through 189 of SEQ ID NO. 2, wherein the polypeptides of a) and b) comprise the G45R SNP and exhibit anti viral and anti-tumoral activity.

48. (Previously Presented) A pharmaceutical composition comprising an isolated polypeptide comprising: a peptide sequence that has an identity of at least 95% with SEQ ID NO. 2, or a portion of said peptide sequence; wherein said polypeptide and said portion comprise the G45R SNP and exhibit anti-viral and anti-tumoral activity.

Claims 49-50 (Cancelled)

51. (New) An isolated polypeptide comprising a peptide sequence having an identity of at least 95% with:

a) the amino acid sequence of SEQ ID NO. 2; or

b) the amino acid sequence of amino acids 24 through 189 of SEQ ID NO. 2, wherein said polypeptide comprises the G45R SNP and exhibits anti-viral activity.

52. (New) An isolated polypeptide comprising a peptide sequence having an identity of at least 95% with:

a) the amino acid sequence of SEQ ID NO. 2; or

b) the amino acid sequence of amino acids 24 through 189 of SEQ ID NO. 2, wherein said polypeptide comprises the G45R SNP and exhibits immunomodulatory activity.

53. (New) An isolated polypeptide comprising a peptide sequence having an identity of at least 95% with:

a) the amino acid sequence of SEQ ID NO. 2; or

b) the amino acid sequence of amino acids 24 through 189 of SEQ ID NO. 2, wherein said polypeptide comprises the G45R SNP and exhibits anti-proliferative activity.

54. (New) An isolated polypeptide comprising a peptide sequence having an identity of at least 99% with:

a) the amino acid sequence of SEQ ID NO. 2; or

b) the amino acid sequence of amino acids 24 through 189 of SEQ ID NO. 2, wherein said polypeptide comprises the G45R SNP and exhibits anti-proliferative activity.

55. (New) An isolated polypeptide comprising a peptide sequence having an identity of more than 99% with:

a) the amino acid sequence of SEQ ID NO. 2; or

b) the amino acid sequence of amino acids 24 through 189 of SEQ ID NO. 2, wherein said polypeptide comprises the G45R SNP and exhibits immunomodulatory activity.

56. (New) An isolated polypeptide comprising a peptide sequence having an identity of at least 99% with:

a) the amino acid sequence of SEQ ID NO. 2; or

b) the amino acid sequence of amino acids 24 through 189 of SEQ ID NO. 2, wherein said polypeptide comprises the G45R SNP and exhibits anti-viral activity.

57. (New) An isolated polypeptide comprising a peptide sequence having an identity of at least 95% with:

a) the amino acid sequence of SEQ ID NO. 2; or

b) the amino acid sequence of amino acids 24 through 189 of SEQ ID NO. 2, wherein said polypeptide comprises the G45R SNP and exhibits anti-viral, immunomodulatory, and/or anti-proliferative activity.

58. (New) An isolated polypeptide comprising a peptide sequence having an identity of at least 99% with:

a) the amino acid sequence of SEQ ID NO. 2;

b) or the amino acid sequence of amino acids 24 through 189 of SEQ ID NO. 2, wherein said polypeptide comprises the G45R SNP and exhibits anti-viral, immunomodulatory, and/or anti-proliferative activity.

59. (New) An isolated polypeptide comprising:

a) the amino acid sequence of SEQ ID NO. 2; or

b) the amino acid sequence of amino acids 24 through 189 of SEQ ID NO. 2, wherein the polypeptides of a) and b) comprise the G45R SNP.

60. (New) A pharmaceutical composition comprising an isolated polypeptide comprising a peptide sequence that has an identity of at least 95% with the amino acid sequence of amino acids 24 through 189 of SEQ ID NO. 2, wherein said polypeptide comprises the G45R SNP and exhibits anti-viral, immunomodulatory, and/or antiproliferative activity.

61. (New) A pharmaceutical composition comprising an isolated polypeptide comprising a peptide sequence that has an identity of at least 99% with the amino acid sequence of amino acids 24 through 189 of SEQ ID NO. 2, wherein said polypeptide comprises the G45R SNP and exhibits anti-viral, immunomodulatory, and/or antiproliferative activity.

62. (New) A pharmaceutical composition comprising an isolated polypeptide comprising amino acids 24 through 189 of SEQ ID NO. 2, wherein said polypeptide comprises the G45R SNP.

63. (New) A pharmaceutical composition according to claim 62, wherein said polypeptide comprising G45R SNP exhibits antiviral, immunomodulatory, and/or antiproliferative activity.

64. (New) A method for treating or preventing a viral disease selected among chronic hepatitis B, chronic hepatitis C, infectious pneumonias, venereal diseases, and genital warts, comprising administering to an individual a therapeutically effective amount of a therapeutic agent comprising the isolated polypeptide of any one of claims 27, 28, 47, 57, 58, or 59, with a pharmaceutically acceptable excipient.

65. (New) A method for treating or preventing metastasizing renal carcinomas, melanomas, lymphomas comprising follicular lymphomas and cutaneous T cell lymphoma, leukemias comprising hairy-cell leukemia, chronic lymphocytic leukemia and chronic myeloid leukemia, cancers of the liver, neck, head and kidneys, multiple myelomas, carcinoid tumors and tumors that appear following an immune deficiency comprising Kaposi's sarcoma in the case of AIDS, comprising administering to an individual a therapeutically effective amount of a therapeutic agent comprising the isolated polypeptide of any one of claims 27, 28, 47, 57, 58, or 59, with a pharmaceutically acceptable excipient.